Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
Francesco Chiarelli, Daniele Di MarzioDepartment of Pediatrics, University of Chieti, ItalyAbstract: Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-04-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | https://www.dovepress.com/peroxisome-proliferator-activated-receptor-gamma-agonists-and-diabetes-peer-reviewed-article-VHRM |